Vedantra Pharmaceuticals Inc. is developing nanoparticle vaccines that are designed to generate a more potent antibody and T cell response than traditional subunit vaccines. By delivering antigens and immunostimulatory adjuvants in multilayer lipid vesicles, the technology mimics the pathogen-associated molecular patterns necessary for a robust immune response.

Subunit vaccines are typically a mixture of one or more antigens from a target pathogen plus an adjuvant. They are effective at triggering an antibody response but often elicit poor or even no T cell responses. That is a problem because many viral diseases are thought to require a highly potent T cell response in addition to an antibody response to control and eradicate infection.